Ruxolitinib
Myelofibrosis and polycythemia vera; topical formulations for vitiligo and atopic dermatitis
- CAS No.
- 941678-49-5
- Indication Class
- Oncology / Hematology
- Patent Expiry
- Off-patent · 2026 (indicative)
- Therapeutic Area
- Oncology / Hematology
- Target / Mechanism
- JAK1·JAK2
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- US compound patent incl. term extension (timing differs by market)
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A foundational agent in myelofibrosis with continued dermatology indication expansion; long-marketed with rigid, predictable demand, a low-volatility steady product.
Oncology / Hematology · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Ruxolitinib is a prescription medication that works by inhibiting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. This targeted action interferes with abnormal signaling pathways that drive certain blood disorders and inflammatory conditions.
Supply source: Unibest · Ruxolitinib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.